Tests RAS(ON) inhibitors in lung cancer with RAS gene mutations
Tests new RAS(ON) inhibitor drugs in adults with advanced RAS-mutated lung cancer.
Plain-language title generated from the registry record
Registry title: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Key facts
- Where
- Copenhagen Oe and Odense C, DenmarkSee the 2 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which best describes your lung cancer?
- Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?
Source: NCT06162221, who can take part
Where in Denmark
- RigshospitaletCopenhagen Oe, DenmarkTaking people
- Odense University HospitalOdense C, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines, Inc.
- Trial code
- NCT06162221EU 2025-521147-21-00
- Record updated
- 19 October 2026
- Original description
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.Read full original descriptionShow less
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.
The first four subprotocols include the following:
Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
Inclusion: All Patients (unless otherwise noted):; ≥ 18 years of age; ECOG PS is 0 to 1; Adequate organ function as outlined by the study; Received prior standard therapy appropriate for tumor type and stage; Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A); Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B); Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D).
Exclusion: Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs; Major surgery < 28 days of first dose; Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids; Other inclusion/exclusion criteria may apply; All Patients:; Primary central nervous system (CNS) tumors.